CN1106690A - Medicine of curing hepatitis - Google Patents
Medicine of curing hepatitis Download PDFInfo
- Publication number
- CN1106690A CN1106690A CN 94118275 CN94118275A CN1106690A CN 1106690 A CN1106690 A CN 1106690A CN 94118275 CN94118275 CN 94118275 CN 94118275 A CN94118275 A CN 94118275A CN 1106690 A CN1106690 A CN 1106690A
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- medicine
- grams
- radix
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 208000006454 hepatitis Diseases 0.000 title claims abstract description 20
- 231100000283 hepatitis Toxicity 0.000 title claims abstract description 17
- 229940079593 drug Drugs 0.000 title description 11
- 241000222336 Ganoderma Species 0.000 claims description 6
- 239000009636 Huang Qi Substances 0.000 claims description 6
- 241000219784 Sophora Species 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 235000020357 syrup Nutrition 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 235000008504 concentrate Nutrition 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000003285 pharmacodynamic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 4
- 241001061264 Astragalus Species 0.000 abstract 1
- 241000893536 Epimedium Species 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 241001648835 Polygonum cuspidatum Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 235000018905 epimedium Nutrition 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 208000002672 hepatitis B Diseases 0.000 description 7
- 206010008909 Chronic Hepatitis Diseases 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 5
- 241000700721 Hepatitis B virus Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 101710142246 External core antigen Proteins 0.000 description 3
- 206010019755 Hepatitis chronic active Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000272525 Anas platyrhynchos Species 0.000 description 2
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 2
- 206010019759 Hepatitis chronic persistent Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The said medicine for hepatitis is prepared with Chinese medicinal material including Epimedium, Polygonum cuspidatum. Paeonia lactiflora, tararacum, Astragalus, etc. It is oral prepn prepared via extraction and concentration. The said medicine prepn has excellent curative effect, i.e., ALT return-to-normal rate being 51.6% and 59.4% for chronic persisting type hepatitis and chromic motive hepatitis respectively, AST return-to-normal rate being 48.4% and 62.3% respectively, and inhibitation rate of HBV-DNA and DNA-P being 76.1% and 78.4% respectively.
Description
What the present invention relates to is that a kind of application drug matching forms, the pharmaceutical formulation of treatment hepatitis and contain the product of this prescription.
Hepatitis B is the viral infectious of serious harm human body health, because the hepatitis B virus range of infection is wide, the easy infection number is many, wherein the hepatitis patient of 10-20% is a chronic hepatitis B, and the Drug therapy difficulty of chronic active hepatitis is big, and quite a few people will be gradually transformed into the trend of liver cirrhosis, its transformation time is that 3-10 does not wait, therefore, the treatment of chronic hepatitis B, not only to suppress virus in vivo duplicate propagation, eliminate its virus, also will recover the normal function of its liver, human body immunity improving could be blocked the badness come-off that liver cirrhosis appears in body.China adopts prescription and the medicine a lot of decoct and the powders as CN1065593A, the spirit of hepatitis B specially good effect of Chinese herbal treatment hepatitis B; The production method of CN1060608A hepatitis record and CN85100392A extract the method for treatment medicine for curing hepatitis from Radix Sophorae Tonkinensis, all have their own characteristics each, but clinical case is observed and there is certain weakness in the clinical practice result, mainly is to the inhibition of hepatitis B virus and removes undesirablely, and curative effect is not high.Existing market product sold polyporusum bellatus treatment hepatitis B, the HBeAg negative conversion rate is 34.2%, and doing well,improving and SGPT normalization rate are 12.8%, 35.1%.And bifendate is used for the chronic hepatitis patient, and the ALT normalization rate is 77.4%, but the knock-on rate of ALT is higher, drug withdrawal after 3 months ALT knock-on rate reach 30-50%, and other liver function index is not had obvious improvement, clinical practice is subjected to great restriction like this.
Also has commercially available hepatitis spirit (Radix Sophorae Tonkinensis) injection, need injection every day, and the HBeAg negative conversion rate is 24%, DNA-P negative conversion rate 24.19%, total effective rate are 46.4%, because the sick particularity of planting of hepatitis, the pharmaceutical effectiveness of clinical practice at present is undesirable, the patient more is badly in need of wanting the curative effect height, and toxicity is low, oral new medicine easy to use.
Clinical practice situation according to the present world, state's internal therapy hepatitis medicament, summed up the sick cause of disease characteristics of planting of hepatitis, summed up effective prescription for the treatment of hepatitis for many years, systematically investigated the peroral dosage form that the compatibility of Chinese crude drug medicine prescription and production technology and optimal clinical are used.
The purpose of this invention is to provide and a kind ofly can improve liver function fast, improve the hepatic pathology performance, adjust immunity of organism, eliminate hepatitis B virus, improve the active drug of the treatment hepatitis B of negative conversion rate.
The present invention is in line with the heat-clearing and toxic substances removing of the traditional Chinese medical science, and the principle of dispersing the stagnated live-QI to relieve the stagnation of QI, conditioning liver stomach, nourishing the liver and kidney, blood circulation promoting and blood stasis dispelling is carried out composition of prescription.Medicine of the present invention contains in parts by weight: Herba Epimedii 10-50 part, Rhizoma Polygoni Cuspidati 5-60 part, Radix Paeoniae Rubra 6-120 part, Herba Taraxaci 10-120 part, Radix Astragali 10-150 part, Radix Et Rhizoma Rhei 5-10 part, Ganoderma 6-30 part, Fructus Ligustri Lucidi 6-45 part, root of subprostrate sophora 5-15 part, Rhizoma Smilacis Glabrae 10-100 part.
Medicine of the present invention is to handle, batching, extract, concentrate (unfinished work check) and the oral formulations made through raw material.Promptly can be: tablet, electuary, capsule, oral liquid, syrup etc. keep the oral formulations of physiology drug effect.
Embodiment 1(low dosage)
With 1 grammes per square metre is 1 part, and its content is: Herba Epimedii 10 grams, Rhizoma Polygoni Cuspidati 10 grams, Radix Paeoniae Rubra 10 grams, Herba Taraxaci 10 grams, the Radix Astragali 10 grams, Radix Et Rhizoma Rhei 5 grams, Ganoderma 10 grams, Fructus Ligustri Lucidi 8 grams, root of subprostrate sophora 5 grams, Rhizoma Smilacis Glabrae 10 grams.
Above medical material is through following PROCESS FOR TREATMENT:
(1) with the Diluted Alcohol 70-85% lixiviate of Ganoderma, Herba Epimedii, Rhizoma Smilacis Glabrae, extracting solution merges.
(2) with Herba Taraxaci, Rhizoma Polygoni Cuspidati, the Radix Astragali, root of subprostrate sophora, Fructus Ligustri Lucidi, Radix Paeoniae Rubra, Radix Et Rhizoma Rhei, add decocting in water, the water extract merges.
(3) will merge with the water extract behind the extracting solution decompression recycling ethanol in (1).Concentrating under reduced pressure becomes thick paste.
(4) with condensed cream oven dry in (3), pulverizing again, cross 80 mesh sieves, is wetting agent with 60% ethanol, is controlled to granule, and oven dry by 20 mesh sieves, is made electuary again, every bag 10 gram, 1 bag/time/day.
(5), be packaged into 10 gram/bags with (4) small particles electuary; Or incapsulate, can be made into every capsules and contain 0.5 gram dose, every day three times, each 6.
(6) or with the thick paste pressing tablet technology of (4), be pressed into 0.5 gram/sheet, tablet, four times a day, each 4.
(7) (1), (2) extracting solution are merged, stir evenly, after the standing over night, the leaching supernatant reclaims ethanol, becomes concentrated solution, adds simple syrup, makes syrup preparation.
The 120ml/ bottle, every day secondary, each 20ml.
Embodiment 2(median dose)
Get Herba Epimedii 30 grams, Rhizoma Polygoni Cuspidati 30 grams, Radix Paeoniae Rubra 60 grams, Herba Taraxaci 60 grams, the Radix Astragali 80 grams, Radix Et Rhizoma Rhei 8 grams, Ganoderma 15 grams, Fructus Ligustri Lucidi 30 grams, root of subprostrate sophora 10 grams, Rhizoma Smilacis Glabrae 60 grams.With above medical material, by process in the example 1 make electuary 10 gram/bags or capsule 0.5 gram/, or tablet 0.5 gram/sheet or syrup 120ml/ bottle.
Embodiment 3(high dose)
Get Herba Epimedii 50 grams, Rhizoma Polygoni Cuspidati 60 grams, Radix Paeoniae Rubra 120 grams, Herba Taraxaci 120 grams, the Radix Astragali 150 grams, Radix Et Rhizoma Rhei 10 grams, Ganoderma 30 grams, Fructus Ligustri Lucidi 45 grams, root of subprostrate sophora 15 grams, Rhizoma Smilacis Glabrae 100 grams are made electuary with above medical material by example 1 process, or capsule or tablet or syrup.
Drug standard of the present invention is all according to " Chinese pharmacopoeia requirement.
Medicine of the present invention confirms through clinical application research and experimentation, takes the medicine that contains this prescription, and (DHBV-DNA DNA-P) improves liver function, suppresses hepatitis B virus duplication, the disposable gastric infusion LD of acute toxicity test in mice can to suppress duck liver virus
50＞141.69(crude drug)/and kg, mice maximum tolerated dose＞247.8g(crude drug)/kg, be equivalent to 112.5 times of clinical consumption.The rat long term toxicity test confirms that low dose group is 5.5 times of clinical dosage, 12g/kg, do not have the overt toxicity reaction, nontoxic substantially, high dose group is 11 times of 24g/kg of clinical dosage, no pathology change and influence, are 51.6% through clinical research ALT normalization rate chronic persistent hepatitis, chronic active hepatitis 59.4%; The AST normalization rate is 48.4%, 62.3%; To chronic persistent hepatitis, chronic active hepatitis HBeAg, DNA-P, HBV-DNA, negative conversion rate be respectively 46.2%, 41.2%, 41.1% and 49.1%, 55.6%, 48.5% and the matched group comparing difference remarkable.Duck liver virus HBV-DNA and DNA-P suppression ratio are respectively 76.1% and 78.4%, are better than matched group, and have no side effect.
Claims (2)
1, a kind of medicine for the treatment of hepatitis, it is characterized in that containing Herba Epimedii 10-50 part in parts by weight, Rhizoma Polygoni Cuspidati 5-60 part, Radix Paeoniae Rubra 6-120 part, Herba Taraxaci 10-120 part, Radix Astragali 10-150 part, Radix Et Rhizoma Rhei 5-10 part, Ganoderma 6-30 part, Fructus Ligustri Lucidi 6-45 part, root of subprostrate sophora 5-15 part, Rhizoma Smilacis Glabrae 10-100 part.
2, the medicine of treatment hepatitis according to claim 1, it is characterized in that this medicine be through raw material handle, batching, extract, concentrate (unfinished work check) and oral formulations that having of making treated the hepatitis pharmacodynamics, promptly can be electuary, tablet, capsule, syrup and oral liquid etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94118275A CN1056755C (en) | 1994-11-19 | 1994-11-19 | Medicine of curing hepatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94118275A CN1056755C (en) | 1994-11-19 | 1994-11-19 | Medicine of curing hepatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1106690A true CN1106690A (en) | 1995-08-16 |
| CN1056755C CN1056755C (en) | 2000-09-27 |
Family
ID=5038733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN94118275A Expired - Fee Related CN1056755C (en) | 1994-11-19 | 1994-11-19 | Medicine of curing hepatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1056755C (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999022749A1 (en) * | 1997-11-05 | 1999-05-14 | Sam Chun Dang Pharm Co., Ltd. | Galenic preparation for prevention and treatment of hepatocarcinoma |
| CN100356958C (en) * | 2006-07-06 | 2007-12-26 | 张砚 | Synergistic medicinal composition for treating hepatitis |
| CN100363040C (en) * | 2006-08-17 | 2008-01-23 | 张娜 | Medicinal compositions comprising biphenyldicarboxylate |
| CN101810759A (en) * | 2010-04-27 | 2010-08-25 | 张大宇 | Curbitacin-containing medicine |
| CN101856384B (en) * | 2009-04-09 | 2011-08-17 | 李佳柔 | Liver-protecting combination |
| CN101721597B (en) * | 2009-12-30 | 2011-12-21 | 宁波市江北威曼生物科技有限公司 | Pharmaceutical composition containing oleanolic acid |
| CN106138260A (en) * | 2015-04-13 | 2016-11-23 | 周海腾 | A kind of Chinese medicine oral liquid treating hepatitis |
| CN107158267A (en) * | 2017-05-26 | 2017-09-15 | 蒋田英 | A kind of medicine for treating hepatitis |
| CN107802710A (en) * | 2017-11-06 | 2018-03-16 | 廖会吉 | A kind of medicine for treating hepatitis B and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1078897A (en) * | 1993-01-03 | 1993-12-01 | 于灵惠 | " hepatitis B health " Chinese medicine preparation and preparation technology thereof |
| CN1044684C (en) * | 1993-08-09 | 1999-08-18 | 张经济 | Compound Chinese caterpillar fungus extract and prepn. therefor |
-
1994
- 1994-11-19 CN CN94118275A patent/CN1056755C/en not_active Expired - Fee Related
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999022749A1 (en) * | 1997-11-05 | 1999-05-14 | Sam Chun Dang Pharm Co., Ltd. | Galenic preparation for prevention and treatment of hepatocarcinoma |
| CN100356958C (en) * | 2006-07-06 | 2007-12-26 | 张砚 | Synergistic medicinal composition for treating hepatitis |
| CN100363040C (en) * | 2006-08-17 | 2008-01-23 | 张娜 | Medicinal compositions comprising biphenyldicarboxylate |
| CN101856384B (en) * | 2009-04-09 | 2011-08-17 | 李佳柔 | Liver-protecting combination |
| CN101721597B (en) * | 2009-12-30 | 2011-12-21 | 宁波市江北威曼生物科技有限公司 | Pharmaceutical composition containing oleanolic acid |
| CN101810759A (en) * | 2010-04-27 | 2010-08-25 | 张大宇 | Curbitacin-containing medicine |
| CN106138260A (en) * | 2015-04-13 | 2016-11-23 | 周海腾 | A kind of Chinese medicine oral liquid treating hepatitis |
| CN107158267A (en) * | 2017-05-26 | 2017-09-15 | 蒋田英 | A kind of medicine for treating hepatitis |
| CN107802710A (en) * | 2017-11-06 | 2018-03-16 | 廖会吉 | A kind of medicine for treating hepatitis B and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1056755C (en) | 2000-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1044974C (en) | Anti- hepatitis B preparation | |
| CN1201776C (en) | Medicines composition for treating diabetes and its prepn | |
| CN1056755C (en) | Medicine of curing hepatitis | |
| CN1243743A (en) | Medicine for treating chronic hepatism and its preparing process | |
| CN1839944A (en) | Granular composition for reducing blood fat and process for producing the same | |
| CN1493315A (en) | Medicine for treating chronic hepatitis B | |
| CN101036779A (en) | Composite medicine for treating hepatopathy and its preparing process | |
| CN1176113A (en) | Compound bufonin of bufo gargarizans | |
| CN104771589A (en) | Traditional Chinese medicine composition for treating fatty liver and application thereof | |
| CN101618156A (en) | Medicine composition for treating hepatitis B and preparation method thereof | |
| CN101007113B (en) | Shenling Chinese medicine preparation for treating acute and chronic hepatitis and its preparation method | |
| CN1969940A (en) | Antivirus pharmaceutical composition | |
| CN1519018A (en) | Combination of medicine for treating hepatitis | |
| CN1136939A (en) | Chinese drugs for curing hepatitis B | |
| CN1086129C (en) | Hepatitis restoration pill | |
| CN1140281C (en) | Yiyuansan powder as one orally taken medicine for treating liver cancer and its preparation | |
| CN110898181A (en) | anti-AIDS medicine and its preparing method | |
| CN1470271A (en) | Chinese medicinal compound preparation for treating liver fibrillation disease and its preparation method | |
| CN1242768C (en) | Hepatitis treating medicine and its preparing process | |
| CN1291729C (en) | Antiviral Chinese medicine prepn of Hypericum perforatumand its prepn process | |
| CN1340353A (en) | Orally-applied medicine for treating hepatism and its preparing process | |
| CN1814250B (en) | Chinese medicine composition for treating liver cirrhosis ascites and preparation method thereof | |
| CN1682814A (en) | Medicine for treating hepatitis B and its preparing process | |
| CN1613475A (en) | Chinese medicine for treating liver diseases | |
| CN1729992A (en) | External bath lotion for epidemic common cold due to wind-cold |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |